Pluripotential Mechanisms of Cardioprotection with HMG-CoA Reductase Inhibitor Therapy

Author： Rosenson R.S.  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.1, Iss.6, 2001-06, pp. : 411-420

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HMG-CoA Reductase Inhibitor (Statin) Therapy and Coronary Atherosclerosis in Japanese Subjects: Role of High-Density Lipoprotein Cholesterol

By Tani Shigemasa   Nagao Ken   Hirayama Atsushi  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 6, 2011-12 ,pp. : 411-417

Adis International

Access to resources Recommend Favorite

Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative: A Critical Review of Potential Benefits and Drawbacks

By Farnier M.  

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 3, 2003-01 ,pp. : 169-178

Adis International

Access to resources Recommend Favorite

Prevalence of Potentially Severe Drug-Drug Interactions in Ambulatory Patients with Dyslipidaemia Receiving HMG-CoA Reductase Inhibitor Therapy

By Bravo Alexandra E. Rätz  

Drug Safety, Vol. 28, Iss. 3, 2005-01 ,pp. : 263-275

Adis International

Access to resources Recommend Favorite

NK-104: a novel synthetic HMG-CoA reductase inhibitor

By Kajinami K.   Mabuchi H.   Saito Y.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2653-2661

Informa Healthcare

Access to resources Recommend Favorite

HMG CoA reductase inhibitor therapy underused after CAGB

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 364, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite